Eliana Merle
Stock Analyst at UBS
(2.07)
# 2,758
Out of 4,778 analysts
75
Total ratings
36.36%
Success rate
-3.64%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eliana Merle
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $109 → $113 | $71.56 | +57.91% | 2 | Feb 20, 2025 | |
| MRNA Moderna | Maintains: Buy | $96 → $78 | $33.87 | +130.29% | 6 | Feb 19, 2025 | |
| ETNB 89bio | Maintains: Buy | $25 → $38 | $8.01 | +374.70% | 3 | Jan 31, 2025 | |
| AKRO Akero Therapeutics | Maintains: Buy | $42 → $109 | $45.26 | +140.83% | 4 | Jan 31, 2025 | |
| ZNTL Zentalis Pharmaceuticals | Maintains: Neutral | $5 → $2.2 | $1.87 | +17.96% | 4 | Jan 28, 2025 | |
| RVMD Revolution Medicines | Maintains: Buy | $65 → $71 | $38.46 | +84.61% | 2 | Jan 8, 2025 | |
| ASND Ascendis Pharma | Initiates: Buy | $196 | $161.11 | +21.66% | 1 | Jan 7, 2025 | |
| TYRA Tyra Biosciences | Initiates: Buy | $28 | $10.32 | +171.32% | 1 | Jan 7, 2025 | |
| SGMT Sagimet Biosciences | Initiates: Buy | $12 | $4.02 | +198.51% | 1 | Nov 12, 2024 | |
| IVA Inventiva | Initiates: Neutral | $3 | $2.80 | +7.14% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $5.89 | +341.80% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $74 | $31.80 | +132.70% | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $411 → $441 | $343.88 | +28.24% | 3 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $23 → $33 | $18.41 | +79.25% | 4 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $97 → $131 | $97.16 | +34.84% | 6 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $2 | $1.56 | +28.21% | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $83 | $23.78 | +249.03% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $253 → $288 | $281.02 | +2.49% | 1 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $47 | $36.77 | +27.82% | 2 | May 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $5 | $3.21 | +55.76% | 3 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $18 | $3.32 | +442.99% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $42 | $14.37 | +192.28% | 4 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $18 | $2.92 | +516.44% | 1 | Jan 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $8 | $1.28 | +525.00% | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $5.66 | +288.69% | 1 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $47 | $8.22 | +471.78% | 1 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $8.63 | +85.40% | 2 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $123 | $8.13 | +1,412.92% | 3 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $192 → $134 | $25.54 | +424.67% | 3 | Aug 19, 2020 |
BioMarin Pharmaceutical
Feb 20, 2025
Maintains: Buy
Price Target: $109 → $113
Current: $71.56
Upside: +57.91%
Moderna
Feb 19, 2025
Maintains: Buy
Price Target: $96 → $78
Current: $33.87
Upside: +130.29%
89bio
Jan 31, 2025
Maintains: Buy
Price Target: $25 → $38
Current: $8.01
Upside: +374.70%
Akero Therapeutics
Jan 31, 2025
Maintains: Buy
Price Target: $42 → $109
Current: $45.26
Upside: +140.83%
Zentalis Pharmaceuticals
Jan 28, 2025
Maintains: Neutral
Price Target: $5 → $2.2
Current: $1.87
Upside: +17.96%
Revolution Medicines
Jan 8, 2025
Maintains: Buy
Price Target: $65 → $71
Current: $38.46
Upside: +84.61%
Ascendis Pharma
Jan 7, 2025
Initiates: Buy
Price Target: $196
Current: $161.11
Upside: +21.66%
Tyra Biosciences
Jan 7, 2025
Initiates: Buy
Price Target: $28
Current: $10.32
Upside: +171.32%
Sagimet Biosciences
Nov 12, 2024
Initiates: Buy
Price Target: $12
Current: $4.02
Upside: +198.51%
Inventiva
Nov 12, 2024
Initiates: Neutral
Price Target: $3
Current: $2.80
Upside: +7.14%
Nov 12, 2024
Initiates: Buy
Price Target: $26
Current: $5.89
Upside: +341.80%
Nov 4, 2024
Maintains: Buy
Price Target: $80 → $74
Current: $31.80
Upside: +132.70%
Nov 1, 2024
Maintains: Buy
Price Target: $411 → $441
Current: $343.88
Upside: +28.24%
Oct 30, 2024
Maintains: Neutral
Price Target: $23 → $33
Current: $18.41
Upside: +79.25%
Sep 18, 2024
Maintains: Neutral
Price Target: $97 → $131
Current: $97.16
Upside: +34.84%
Sep 9, 2024
Maintains: Neutral
Price Target: $10 → $2
Current: $1.56
Upside: +28.21%
Aug 9, 2024
Maintains: Buy
Price Target: $85 → $83
Current: $23.78
Upside: +249.03%
Jun 28, 2024
Maintains: Buy
Price Target: $253 → $288
Current: $281.02
Upside: +2.49%
May 28, 2024
Maintains: Buy
Price Target: $51 → $47
Current: $36.77
Upside: +27.82%
Apr 4, 2024
Maintains: Neutral
Price Target: $3 → $5
Current: $3.21
Upside: +55.76%
Mar 27, 2024
Maintains: Buy
Price Target: $19 → $18
Current: $3.32
Upside: +442.99%
May 19, 2023
Maintains: Buy
Price Target: $45 → $42
Current: $14.37
Upside: +192.28%
Jan 19, 2023
Upgrades: Buy
Price Target: $18
Current: $2.92
Upside: +516.44%
Dec 7, 2022
Maintains: Buy
Price Target: $19 → $8
Current: $1.28
Upside: +525.00%
Oct 13, 2022
Initiates: Buy
Price Target: $22
Current: $5.66
Upside: +288.69%
Jun 23, 2022
Maintains: Buy
Price Target: $51 → $47
Current: $8.22
Upside: +471.78%
May 21, 2021
Initiates: Buy
Price Target: $16
Current: $8.63
Upside: +85.40%
May 21, 2021
Initiates: Buy
Price Target: $123
Current: $8.13
Upside: +1,412.92%
Aug 19, 2020
Maintains: Neutral
Price Target: $192 → $134
Current: $25.54
Upside: +424.67%